6 completed, 1 not yet recruiting, 1 terminated, 1 unknown. 9 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Not yet recruiting 1, Terminated 1, Unknown 1 |
| Phase 1 | 5 | Completed 3, Terminated 1, Unknown 1 |
Follow RNA, Messenger: new trials by email Literature Review of RNA, Messenger trials Research Report on RNA, Messenger
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety of the Acne mRNA Vaccine in Adolescents 12 to 17 Years of Age With Moderate to Severe Acne Acne mRNA (messenger ribonucleic acid) vaccine, Placebo - Acne | Phase 2 | Not yet recruiting | Sanofi | 410 | 2026-10-30 | 2026-09-18 |
| A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1, TIV mRNA-neuraminidase (NA), TIV mRNA-HA Vaccine 2 - Influenza, Healthy Volunteers | Phase 1 / Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 1162 | 2025-01-06 | 2026-06-09 |
| Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) Part1:Recombinant two-component COVID-19 vaccine (CHO cell), Part1: Placebo, Part2: Recombinant two-component COVID-19 vaccine (CHO cell) - COVID-19 | Phase 2 | Completed | Jiangsu Rec-Biotechnology Co., Ltd. | 948 | 2022-01-31 | 2024-02-29 |
| COVID-19 Protection After Transplant Pilot Study BNT162b2 vaccine (Pfizer/BioNTech), mRNA-1273 vaccine (Moderna) - Kidney Transplant Recipients | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 81 | 2021-08-10 | 2025-07-30 |
| A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy Messenger ribonucleic acid (mRNA)-1273 Vaccine, Messenger ribonucleic acid (mRNA)-1273 Vaccine Booster, ECG - Solid Tumor Malignancy, Hematologic Malignancy | Phase 2 | Completed | National Cancer Institute (NCI) | 19 | 2021-04-28 | 2024-08-27 |
| A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects mRNA-transfected autologous dendritic cells, autologous dendritic cells with no mRNA transfection - HIV-1 Infection, HIV Infections | Phase 1 / Phase 2 | Completed | Massachusetts General Hospital | 15 | 2009-08-01 | 2016-03-08 |
| Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients autologous dendritic cells electroporated with mRNA - Uveal Melanoma | Phase 1 / Phase 2 | Terminated | Radboud University Medical Center | 23 | 2009-06-01 | 2018-12-07 |
| Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma Patients mRNA, GM-CSF s.c. - Malignant Melanoma | Phase 1 / Phase 2 | Completed | University Hospital Tuebingen | 20 | 2004-07-01 | 2007-04-19 |
| Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy Peptide vaccine, Montanide ISA-51, Granulocyte macrophage colony stimulating factor (GM-CSF) - Recurrent Prostate Cancer | Phase 1 / Phase 2 | Unknown | University Hospital Tuebingen | 36 | 2004-04-01 | 2017-08-17 |
Acne Vulgaris (1) · COVID-19 (1) · HIV Infections (1) · Hematologic Neoplasms (1) · Influenza, Human (1) · Leukemia (1) · Lymphoma (1) · Melanoma (1) · Multiple Myeloma (1) · Prostatic Neoplasms (1) · Uveal Melanoma (1)
University Hospital Tuebingen (2) · Jiangsu Rec-Biotechnology Co., Ltd. (1) · Massachusetts General Hospital (1) · National Cancer Institute (NCI) (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Radboud University Medical Center (1) · Sanofi (1) · Sanofi Pasteur, a Sanofi Company (1)
United States (4) · Australia (1) · Germany (1) · Netherlands (1) · Philippines (1)
Arnulf Stenzl, Prof. (1) · Claus Garbe, Prof. Dr. (1) · Cornelis JA Punt, prof.MD (1) · Dorry L. Segev, MD, PhD (1) · James Gulley, M.D. (1) · Rajesh Gandhi, MD (1)
PMID 19609242, PMID 36966905, PMID 38019656, PMID 38103161, PMID 38529685
R01AI066992 (1)